Quantum BioPharma Ltd. (QNTM)
QNTM Stock Price Chart
Explore Quantum BioPharma Ltd. interactive price chart. Choose custom timeframes to analyze QNTM price movements and trends.
QNTM Company Profile
Discover essential business fundamentals and corporate details for Quantum BioPharma Ltd. (QNTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
—
Employees
—
Website
https://www.quantumbiopharma.comCEO
Zeeshan Saeed
Description
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
QNTM Financial Timeline
Browse a chronological timeline of Quantum BioPharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 10 Nov 2025
EPS estimate is -$0.20.
Earnings released on 6 Aug 2025
EPS came in at -$3.23 falling short of the estimated -$0.17 by -1.80K%.
Earnings released on 14 May 2025
EPS came in at -$1.41 falling short of the estimated -$0.37 by -281.08%, while revenue for the quarter reached $2.17M , meeting expectations.
Earnings released on 28 Mar 2025
EPS came in at -$2.89 falling short of the estimated -$0.80 by -261.25%.
Stock split effective on 15 Aug 2024
Shares were split 1 : 65 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at -$5.20 falling short of the estimated -$3.90 by -33.33%.
Earnings released on 14 May 2024
EPS came in at -$3.25 matching the estimated -$3.25.
Earnings released on 28 Mar 2024
EPS came in at -$0.04 surpassing the estimated -$9.31 by +99.57%.
Earnings released on 15 Nov 2023
EPS came in at -$1.95 surpassing the estimated -$9.09 by +78.53%.
Earnings released on 20 Jul 2023
EPS came in at -$9.31 .
Earnings released on 31 Mar 2023
Earnings released on 11 Nov 2022
Earnings released on 15 Nov 2021
EPS came in at -$9.57 .
Earnings released on 12 Aug 2021
EPS came in at -$22.88 .
QNTM Stock Performance
Access detailed QNTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.